Date: Thu, 18 Dec 1997 17:52:59 GMT Server: Apache/1.2.4 Last-Modified: Thu, 30 Oct 1997 19:28:58 GMT ETag: "976c-eb9-3458dffa" Content-Length: 3769 Accept-Ranges: bytes Connection: close Content-Type: text/html
Corporate Partnering Opportunities
Avigen is actively seeking to develop long-term strategic collaborations with pharmaceutical companies that can provide funding for research and development activities and clinical trials for potential products of the sponsor. . We also are looking for new applications to disease, and for new gene sequences to deliver. We and our collaborators have delivered over thirty different genes, so we can do custom development programs on applications that would fit the product lines and/or research interests of most pharmaceutical companies.
Our excitement about our system rests on a combination of animal and production run data. Avigens AAV delivery system is unusual in its ability to achieve efficient delivery of a wide variety of genes to many different target tissues, including muscle, liver, CNS, and skin. Product would be directly administered in a vial/syringe format familiar to the medical community. Our system has repeatedly demonstrated prolonged therapeutic response after a single injection; up to eighteen months in one case, combined with a dose-response relationship. Our vectors have no viral genes, and our production process is free of infectious contaminant viruses. Both helper viruses and wild-type AAV viruses have been removed from the process. For more information see Additional Information on Avigens AAV delivery system. We currently have the production capability to move into large animal experimentation and Phase I clinicals.
For further information, please contact Robert Maurer, Vice President of Business Development, at (510) 748-7103, (510) 748-7155 (fax), or at maurer@avigen.com.